BioXcel Therapeutics, Inc.
BTAI
$1.31
$0.064.80%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -63.28% | -71.67% | -66.96% | -63.88% | 5.47% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -63.28% | -71.67% | -66.96% | -63.88% | 5.47% |
| Cost of Revenue | -79.16% | -92.35% | -52.42% | 55.19% | 56.01% |
| Gross Profit | 209.29% | 291.80% | -184.80% | -221.26% | -153.30% |
| SG&A Expenses | -18.35% | -40.58% | -48.04% | -59.26% | -63.16% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.89% | -24.10% | -33.07% | -52.32% | -63.05% |
| Operating Income | 0.69% | 22.43% | 32.03% | 52.06% | 63.91% |
| Income Before Tax | -88.04% | -17.28% | 3.92% | 52.75% | 73.82% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -88.04% | -17.28% | 3.92% | 52.75% | 73.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -88.04% | -17.28% | 3.92% | 52.75% | 73.82% |
| EBIT | 0.69% | 22.43% | 32.03% | 52.06% | 63.91% |
| EBITDA | 0.64% | 22.53% | 32.15% | 52.21% | 64.05% |
| EPS Basic | 57.59% | 74.15% | 71.84% | 77.72% | 83.69% |
| Normalized Basic EPS | 54.54% | 73.24% | 71.13% | 77.74% | 84.39% |
| EPS Diluted | 57.59% | 74.15% | 71.84% | 77.72% | 83.69% |
| Normalized Diluted EPS | 54.54% | 73.24% | 71.13% | 77.74% | 84.39% |
| Average Basic Shares Outstanding | 417.46% | 380.89% | 234.79% | 126.31% | 75.64% |
| Average Diluted Shares Outstanding | 417.46% | 380.89% | 234.79% | 126.31% | 75.64% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |